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Background: The malaria situation has been worsening in Angola, partly due to armed conflict until the recent
past and drug-resistant Plasmodium falciparum. Malaria transmission is heterogeneous within the country, and data
on drug-resistant malaria in different parts of the country are incomplete. The aim of the present study was to
evaluate resistance to 4-aminoquinolines and antifolate drugs in P. falciparum isolates collected in Benguela province,
central Angola, using molecular markers.
Methods: Fingerprick capillary blood was collected from asymptomatic children aged less than 15 years old during a
household survey in and around Balombo town in 2010–2011. Samples were screened for P. falciparum by nested PCR.
Molecular markers (P. falciparum dihydrofolate reductase [pfdhfr], P. falciparum dihydropteroate synthase [pfdhps],
P. falciparum chloroquine resistance transporter [pfcrt], and P. falciparum multidrug-resistance gene 1 [pfmdr1])
were sequenced to determine the key codons associated with drug resistance.
Results: A total of 60 blood samples were positive for P. falciparum. Most isolates with successful PCR
amplification had mutant pfdhfr alleles, with either double mutant AICNI (69%) or triple mutant AIRNI (21%)
haplotypes. A16V, S108T, and I164L substitutions were not found. Many of the isolates were carriers of either
SGKAA (60%) or AGKAA (27%) pfdhps haplotype. K540E substitution was absent. There were only two pfcrt
haplotypes: wild-type CVMNK (11%) and mutant CVIET (89%). Wild-type pfmdr1 NYSND haplotype was found in
19% of the isolates, whereas single mutant pfmdr1 YYSND and NFSND haplotypes occurred in 48% and 11%,
respectively. Double mutant pfmdr1 haplotypes (YFSND and YYSNY) occurred rarely.
Conclusions: The results suggest that the high prevalence of mutant pfcrt CVIET haplotype is in agreement with
low clinical efficacy of chloroquine observed in earlier studies and that the double pfdhfr mutant AICNI and
single pfdhps mutant SGKAA are currently the predominant haplotypes associated with antifolate resistance in
Benguela province. The hallmark of clinical resistance observed in East Africa, i.e. triple pfdhfr mutant haplotype
(AIRNI) and double pfdhps mutant haplotype (SGEAA), was absent. These molecular findings need to be further
evaluated in parallel with clinical studies, in particular with the efficacy of intermittent preventive treatment using
sulphadoxine-pyrimethamine in pregnant women and artesunate-amodiaquine for uncomplicated malaria.
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Malaria is one of the major causes of morbidity and
mortality in Angola. It is responsible for 35% of medical
consultations, 20% of hospitalizations, and 25% of ma-
ternal deaths [1,2]. In 2010, the Angolan Ministry of
Health reported that, of the estimated total population
of 18–20 million, 3.7 million cases of malaria occurred,
mostly due to Plasmodium falciparum [2].
Malaria is endemic throughout the country, but the
transmission pattern is heterogeneous, varying from
intense transmission and hyperendemicity in northern
Angola to seasonal or epidemic, unstable malaria in
the southern part of the country. In central Angola,
including Benguela province, malaria transmission is
characterized as meso-endemic and stable [2].
One of the causes of the worsening malaria situation
in Angola was the civil war that ravaged the country and
paralyzed the health system for three decades, until
2002. Another probable cause is drug-resistant malaria.
The first chloroquine-resistant cases in the country were
reported in non-immune expatriates returning to Europe
from Angola in 1984 [3,4]. Low to moderate therapeutic
efficacies of chloroquine, sulphadoxine-pyrimethamine,
and amodiaquine monotherapies were confirmed in cen-
tral Angola in 2002 [5]. Artemisinin-based combination
therapy (ACT), using either artesunate-amodiaquine,
artesunate-sulphadoxine-pyrimethamine, or artemether-
lumefantrine, is highly effective [5,6]. Since 2006, the
first-line drug for the treatment of uncomplicated
malaria in Angola is artemether-lumefantrine, with
artesunate-amodiaquine as an alternative drug
combination.Figure 1 Map of Angola showing Benguela province and Balombo.In the face of challenges posed by the malaria situ-
ation, several clinical and epidemiological studies have
been undertaken in recent years, including malaria indi-
cator surveys covering the entire Angolan territory [2,7].
However, many of these recent studies have been con-
ducted in Luanda, the capital city, its neighbouring prov-
inces, or in the northern provinces [8-14]. Data from
Benguela province are scarce. The aim of the present
study was to analyse the epidemiology of drug-resistant
P. falciparum isolates using molecular markers in several
localities in and near the town of Balombo.Methods
Study sites
The study was conducted in 2010–2011 in the town of
Balombo and its surrounding villages, situated in Benguela
province in central Angola (Figure 1). Balombo (12°21’26”
south, 14°46’16” east) is located about 150 km east of the
coastal town of Lobito (12°19’11” south, 13°35’59” east)
and 420 km to the south of Luanda (8°50’17” south, 13°
14’3” east), the capital city of Angola. The estimated total
population of Balombo and its surrounding villages was
48,465 inhabitants. The town is located in a valley sur-
rounded by hills.
Benguela region has an equatorial climate character-
ized by a short dry season (June–September) and a long
rainy season (October–May), with an average annual
rainfall of 600–700 mm. Its geography is composed of
savannah forests, with areas along the rivers covered by
tropical forest. The major malaria vector in Benguela
province is Anopheles gambiae s.l. [15,16].
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sumptive malaria accounted for 46% of consultations
and 62% of hospitalizations in 2005. However, since
most malaria cases are diagnosed on a presumptive
basis, the true prevalence of malaria is unknown in areas
around Balombo. Nonetheless, a recent study has shown
that malaria is highly prevalent in Benguela province
and that severe and complicated malaria occurs in both
children and adults [17].
Asymptomatic Plasmodium falciparum carriers
The present study was part of household surveys con-
ducted during the rainy season by the joint teams of
Malaria Control Programme of Société nationale de
métallurgie (Sonamet) and Services Nationaux de Santé
Publique (Angolan Ministry of Health) of Benguela
province. Households were selected by cluster sampling
to obtain 30 representative households in the study sites.
A number was assigned to the households, which were
randomly selected using a table of random numbers.
After obtaining a written informed consent signed by
the head of each household on behalf of all household
members, fingerprick capillary blood was obtained from
the target group, i.e. children aged less than 15 years old,
to prepare thick smears and store blood on Whatman
3MM filter paper. In this household survey, clinical
examination was not performed, and the enrolled chil-
dren were asymptomatic. Blood smears were immedi-
ately stained using 10% Giemsa and examined in the
field. Parasites were counted against 50 white blood cells
for rapid screening in the field. As this household survey
on asymptomatic children was part of a training session
of inexperienced Angolan laboratory technicians, the
gold standard for malaria diagnosis was PCR in this
study. If a child was smear-positive and presented fever
or other signs and symptoms suggestive of malaria, he
or she was referred to the nearest health centre for fur-
ther examination and appropriate treatment.
Ethical approval
This study was reviewed and approved by the National
Malaria Control Programme of the Angolan Ministry of
Health, the ethical authority that approves clinical stud-
ies on malaria research in Angola.
DNA extraction and PCR
DNA was extracted from Whatman 3MM filter papers
using Chelex beads [18]. Briefly, a 2 mm diameter disc
was cut from Whatman filter paper and incubated at 4°C
overnight in 0.5 mL of phosphate-buffered saline (PBS)
containing 0.5% saponin. The filter paper was rinsed twice
in saponin-free PBS, placed in 100 μL of distilled water
containing 10% Chelex, and incubated at 100°C for 20 min
to elute DNA. The supernatant containing extracted DNAwas conserved at -20°C. A diagnostic nested PCR was per-
formed using 18S rRNA as the target gene to detect sam-
ples with P. falciparum [19].
Molecular markers for drug resistance analysed in the
present study (P. falciparum dihydrofolate reductase
[pfdhfr], P. falciparum dihydropteroate synthase [pfdhps],
P. falciparum chloroquine resistance transporter [pfcrt],
and P. falciparum multidrug-resistance gene 1 [pfmdr1])
were amplified by nested PCR, as described in previous
studies [20-22]. PCR products were sequenced using
the Sanger dideoxy method. Nucleotide sequences were
analysed using Chromas 2.4.1 software for DNA se-
quencing (Technelysium Pty Ltd., South Brisbane,
Australia) and aligned using MultAlin software to iden-
tify mutations [23].
Data interpretation and statistical calculations
A total of 576 children aged less than 15 years old were
enrolled in the present household survey. The sample
size was calculated on the basis of an expected smear-
positive rate of 25% determined in an earlier pilot study
in Balombo, risk of error of 5%, and 5% precision.
The sequences of the following key codons were de-
termined: Ala16Val, Asn51Ile, Cys59Arg, Ser108Asn
or Ser108Thr, and Ile164Leu for pfdhfr; Ser436Ala,
Ala437Gly, Lys540Glu, Ala581Gly, and Ala613Thr or
Ala613Ser for pfdhps; codons Cys72Ser, Val73 (invari-
able), Met74Ile, Asn75Glu, Lys76Thr for pfcrt; and
Asn86Tyr, Tyr184Phe, Ser1034Cys, Asn1042Asp, and
Asp1246Tyr for pfmdr1. Based on these codons, differ-
ent haplotypes were determined and compared. Wild-
type pfdhfr haplotype was defined as ANCSI. Double
pfdhfr mutant alleles were defined as Ile-51/Asn-108 or
Arg-59/Asn-108 (AICNI or ANRNI haplotypes). Triple
pfdhfr mutant alleles were defined as Ile-51/Arg-59/
Asn-108 (AIRNI haplotype). Wild-type pfdhps refers to
SAKAA haplotype. Pfcrt haplotype was defined as wild-
type CVMNK and chloroquine-resistant type CVIET.
Wild-type pfmdr1 haplotype denotes NYSND.
Results and discussion
A total of 386 blood samples collected in and around
Balombo town were screened for the presence of malaria
parasites by microscopy and nested PCR. Sixty-one and
80 samples were positive for P. falciparum by micros-
copy and diagnostic nested PCR, respectively. Sixty
PCR-positive samples were further analysed to deter-
mine the key codons of pfdhfr, pfdhps, pfcrt, and pfmdr1
genes.
Fifty-eight of 60 samples were successfully amplified to
determine pfdhfr alleles. A large majority (69%) carried
double Ile-51/Asn-108 mutations, while only 3 (5.2%)
had the alternative Arg-59/Asn-108 double mutations
(Table 1). Triple pfdhfr mutant alleles (AIRNI haplotype)
Table 1 pfdhfr, pfdhps, pfcrt, and pfmdr1 haplotypes of
Plasmodium falciparum isolates in Balombo area,
Benguela province, central Angola
Molecular marker (no. of isolates analysed) No. of isolates (%)
dhfr (n = 58)
Wild-type haplotype ANCSI 2 (3.4)
Single mutant haplotype ANCNI 1 (1.7)
Double mutant haplotype AICNI 40 (69.0)
Double mutant haplotype ANRNI 3 (5.2)
Triple mutant haplotype AIRNI 12 (20.7)
dhps (n = 30)
Wild-type haplotype SAKAA 4 (13.3)
Single mutant haplotype SGKAA 18 (60.0)
Double mutant haplotype AGKAA 8 (26.7)
pfcrt (n = 36)
Wild-type haplotype CVMNK 4 (11.1)
Mutant haplotype CVIET 32 (88.9)
pfmdr1 (n = 54)
Wild-type haplotype, NYSND 19 (35.2)
Single mutant haplotype, YYSND 26 (48.1)
Single mutant haplotype, NFSND 6 (11.1)
Double mutant haplotype, YFSND 2 (3.7)
Double mutant haplotype, YYSNY 1 (1.8)
For each haplotype, mutant alleles are in bold.
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(n = 2; 3.4%) and single Asn-108 mutant allele (n = 1;
1.7%) were rarely observed. All isolates had the wild-type
Ile-164 allele.
In a study on 21 isolates collected in Huambo, a
neighbouring province to the east of Benguela province,
all carried the mutant Asn-108 pfdhfr allele, and the
double mutant haplotype Ile-51/Asn-108 was the most
prevalent [24]. Overall, in that study, 25% of the isolates
collected from different localities in the country pre-
sented the triple pfdhfr mutant alleles. In another study
on isolates collected in Luanda [25], 31 of 61 (51%) sam-
ples were triple pfdhfr mutants, and 25 of 61 (41%) and
4 of 61 (6.6%) isolates were Ile-51/Asn-108 and Arg-59/
Asn-108 double mutants, respectively. In the northern
province of Uige, the majority (40 of 66, 61%) of clinical
isolates were double Ile-51/Asn-108 pfdhfr mutants,
followed by triple mutants (23 of 66, 35%) and the
alternative double Arg-59/Asn-108 mutant (n = 1) and
wild-type (n = 2) [26]. The results of several recent
studies, including those of the present study, suggest
that the double pfdhfr mutant AICNI is currently the
predominant haplotype in several regions in Angola,
with the possible exception of Luanda where triple
pfdhfr mutants seem to predominate.Thirty isolates were randomly selected for sequencing
of pfdhps alleles. Most (60%) were characterized by the
single mutant Gly-437, i.e. SGKAA haplotype (Table 1).
The double mutant haplotype AGKAA and wild-type
SAKAA were found in 8 (26.7%) and 4 (13.3%) isolates,
respectively. Mutations were not observed in codons
540, 581, or 613.
Similarly, in Luanda, SGKAA was also the most fre-
quent haplotype (18 of 30, 60%), followed by AGKAA (7
of 30, 23%) and the wild-type SAKAA (2 of 30, 7%) [25].
SGEAA and SGEGA haplotypes were found in 3 isolates
in that study. The presence of Glu-540 pfdhps allele at a
low frequency (14 of 221 samples, 6.3%) was also re-
ported from an earlier study in Luanda [27]. In a study
on P. falciparum isolates from different parts of the
country [24], SGKAA haplotype largely predominated
over other pfdhps haplotypes (339 of 372, 91%). In that
study, there were 5 isolates with SGKAA, 1 SGEAA, and
2 SAKAA among 8 isolates collected from Huambo, the
neighbouring province of Benguela. The wild-type
SAKAA (21 of 372, 5.6%) and double mutant haplotype
SGEAA (12 of 372, 3.2%) were found at low frequencies
in different regions of Angola. In the northern province,
most isolates were characterized by AGKAA (34 of 66,
51.5%), SGKAA (27 of 66, 40.9%), and SAKAA (5 of 66,
7.6%) [26]. Taken together, SGKAA is the major pfdhps
haplotype in Angola, including Benguela province, and
there appears to be a regional variation in the frequency
of AGKAA haplotype. Both Glu-540 mutant allele and
the wild-type SAKAA haplotype occur at low frequen-
cies. These molecular data need to be interpreted in the
light of clinical efficacy of sulphadoxine-pyrimethamine
for intermittent preventive treatment in pregnancy.
Among 36 isolates randomly selected for PCR amplifica-
tion and sequencing of pfcrt, a large majority (88.9%) were
characterized by the mutant haplotype CVIET. The other
isolates were of wild-type haplotype CVMNK. Ser-72 was
not found in the present study.
In one of the studies conducted in Luanda in which
only codon 76 was determined, Thr-76 was found in 230
of 241 (94%) isolates [27]. In the second study in
Luanda, the mutant pfcrt haplotypes included the South
American-type SVMNT (58 of 102, 57%), CVIET (13 of
102, 13%), and minor and mixed haplotypes [28]. The
pfcrt SVMNT haplotype has been rarely reported from
the African continent. This haplotype is more commonly
found in South America and in some Asian countries
and is associated with resistance to amodiaquine and
chloroquine [29]. It has been hypothesized that the un-
usual predominance of SVMNT in Luanda may possibly
be due to frequent travels and commercial exchanges be-
tween the Angolan capital city and Brazil [28]. However,
other molecular studies conducted elsewhere in Angola,
including the present study, have not reported the
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inces in the north, only two pfcrt haplotypes were ob-
served: CVIET (273 of 430, including mixed haplotypes,
63.5% in Bengo; 62 of 66 isolates, 94% in Uige) and
CVMNK (157 of 430, excluding mixed haplotypes,
36.5% in Bengo; 4 of 66, 6% in Uige) [26,30]. With the
exception of SVMNT haplotype found in Luanda, the
results of the present study, as well as those performed
earlier in other provinces, indicate that most isolates are
carriers of mutant CVIET haplotype and are in agree-
ment with the high prevalence of chloroquine-resistant
P. falciparum in Angola.
Of 54 isolates analysed in the present study, most (29 of
54, 53.7%) carried the mutant pfmdr1 allele Tyr-86, but
mutations occurred less frequently in codons 184 (8 of 54,
14.8%) and 1246 (1 of 54, 1.9%). All isolates had the wild-
type Ser-1034 and Asn-1042 pfmdr1 codons.
In an early study, of 15 Angolan P. falciparum isolates
(11 chloroquine-resistant and 4 chloroquine-sensitive
in vitro), the majority (73%) of chloroquine-resistant iso-
lates carried the mutant Tyr-86 [31]. In Luanda, pure
Tyr-86 allele and Tyr- and Asn-86 mixed alleles were
found in 142 of 199 (71%) isolates [27]. In the northern
province of Uige, many isolates (45 of 66, including
mixed Asn- and Tyr-86; 68%) also had the mutant Tyr-
86 [26]. However, in Bengo province, the pure wild-
type Asn-86 was predominant (94 of 138, 68%), mutant
Phe-184 (pure or mixed alleles) occurred in 54 of 138
isolates (39.1%), and codons 1034, 1042, and 1246 were
all wild-type [30]. These studies indicate that the ma-
jority of Angolan isolates carry the mutant Tyr-86
pfmdr1 allele.
Amodiaquine, in combination with artesunate, is widely
used in sub-Saharan African countries. Previous studies
have suggested that failure after amodiaquine treatment is
associated with the selection of P. falciparum isolates car-
rying pfcrt Thr-76 allele and pfmdr1 haplotype Tyr-86,
Tyr-184, and Tyr-1246 [32-34]. In the present study, most
isolates had the mutant pfcrt Thr-76 allele but the pfmdr1
mutant haplotype associated with amodiaquine resistance
was rare (1 of 54 isolates, 1.8%). These molecular findings
suggest amodiaquine efficacy but require clinical valid-
ation studies in Benguela, Angola.
Conclusions
The results of the present study suggest that the high
prevalence of mutant pfcrt CVIET haplotype is in agree-
ment with low clinical efficacy of chloroquine observed
in an earlier study conducted in the neighbouring prov-
ince [5]. However, the pfmdr1 haplotype associated with
amodiaquine failure was rare, suggesting amodiaquine
efficacy. In Benguela province, the double pfdhfr mutant
AICNI and single pfdhps mutant SGKAA are currently
the predominant haplotypes associated with antifolateresistance. The hallmark of clinical resistance observed
in East Africa, i.e. triple pfdhfr mutant haplotype
(AIRNI) and double pfdhps mutant haplotype (SGEAA),
was absent. These molecular findings need to be further
evaluated in parallel with clinical studies, in particular
with the efficacy of intermittent preventive treatment
using sulphadoxine-pyrimethamine in pregnant women
and therapeutic efficacy of artesunate-amodiaquine.
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